Clinical development of levetiracetam for amyotrophic lateral sclerosis.
This month's Spotlight on... focuses on the current clinical development of the antiepileptic drug levetiracetam for amyotrophic lateral sclerosis. We highlight the experimental rationale behind its progress into patient cohorts with regards to targeting three currently untreatable aspects of human amyotrophic lateral sclerosis: cramps, spasticity and disease progression.
Davies
S L
SL
Moral
M A
MA
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D000077287:Levetiracetam; D009120:Muscle Cramp / Q000188:drug therapy; D009128:Muscle Spasticity / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000927:Anticonvulsants; D018696:Neuroprotective Agents; D000077287:Levetiracetam; D010889:Piracetam